G Bianchi1, A Sambri2, A Righi3, A P Dei Tos4, P Picci3, D Donati1. 1. Department of Orthopedic Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy. 2. Department of Orthopedic Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy. Electronic address: andrea_sambri@libero.it. 3. Department of Pathology, Istituto Ortopedico Rizzoli, Bologna, Italy. 4. Department of Pathology, General Hospital of Treviso, Treviso, Italy.
Abstract
INTRODUCTION: The diagnosis of synovial sarcoma (SS) is currently based on clinical, morphological, immunohistochemical and cytogenetic data. Some of these factors such as grade and histology, specific translocations (SS18-SSX1 vs. SS18-SSX2) and the reduced expression of INI1, were proposed as prognostic variables. The aim of this study was to verify whether histological (grading and histology) and molecular (type of SSX translocation and INI1 expression) characteristics of SS influence the prognosis of the disease. MATERIAL AND METHODS: We retrospectively evaluated 196 patients affected by SS of the extremities treated at our Institution (Istituto Ortopedico Rizzoli, Bologna, Italy). All cases were histologically revised and tumor grade was assessed according to the FNLCC system. Tissue specimens were retrospectively evaluated to check for SS18-SSX fusion type and INI1 expression. RESULTS: Most SS were monophasic, 28% were biphasic. Eighty tumors (41%) were grade 3. Sixty percent harbored SSX1 translocation, 40% SSX2; 51% maintained the expression of INI1. Sarcoma specific survival (OS) was 56.6% at 5 years and 46.9% at 10 years. Prognosis was worse in those patients monophasic SS (p = 0.011) as in those with a grade 3 tumors (p = 0.083). No correlation was found neither between SSX fusion type nor INI1 expression and survival. LR-free survival was 78.9% at 5 years and 75.9% at 10 years. A higher LR rate was observed in tumors with SSX2 translocation and (p = 0.049) in grade 3 SS (0 = 0.028). DISCUSSION: Our data confirm that not all cases of SS present the same severe outcome. High-risk patients identified on the basis of these parameters may qualify for an aggressive treatment approach.
INTRODUCTION: The diagnosis of synovial sarcoma (SS) is currently based on clinical, morphological, immunohistochemical and cytogenetic data. Some of these factors such as grade and histology, specific translocations (SS18-SSX1 vs. SS18-SSX2) and the reduced expression of INI1, were proposed as prognostic variables. The aim of this study was to verify whether histological (grading and histology) and molecular (type of SSX translocation and INI1 expression) characteristics of SS influence the prognosis of the disease. MATERIAL AND METHODS: We retrospectively evaluated 196 patients affected by SS of the extremities treated at our Institution (Istituto Ortopedico Rizzoli, Bologna, Italy). All cases were histologically revised and tumor grade was assessed according to the FNLCC system. Tissue specimens were retrospectively evaluated to check for SS18-SSX fusion type and INI1 expression. RESULTS: Most SS were monophasic, 28% were biphasic. Eighty tumors (41%) were grade 3. Sixty percent harbored SSX1 translocation, 40% SSX2; 51% maintained the expression of INI1. Sarcoma specific survival (OS) was 56.6% at 5 years and 46.9% at 10 years. Prognosis was worse in those patients monophasic SS (p = 0.011) as in those with a grade 3 tumors (p = 0.083). No correlation was found neither between SSX fusion type nor INI1 expression and survival. LR-free survival was 78.9% at 5 years and 75.9% at 10 years. A higher LR rate was observed in tumors with SSX2 translocation and (p = 0.049) in grade 3 SS (0 = 0.028). DISCUSSION: Our data confirm that not all cases of SS present the same severe outcome. High-risk patients identified on the basis of these parameters may qualify for an aggressive treatment approach.
Authors: Yitian Wang; Minxun Lu; Yong Zhou; Sisi Zhou; Xinzhu Yu; Fan Tang; Yi Luo; Wenli Zhang; Hong Duan; Li Min; Chongqi Tu Journal: Cancer Manag Res Date: 2020-07-01 Impact factor: 3.989
Authors: Kenneth Seier; Chaitanya Bandlamudi; Evan Rosenbaum; Mark Dickson; Mrinal Gounder; Mary L Keohan; Ping Chi; Ciara Kelly; Sujana Movva; Benjamin Nacev; Noemi Simeone; Mark Donoghue; Emily K Slotkin; Li-Xuan Qin; Cristina R Antonescu; William D Tap; Sandra P D'Angelo Journal: Clin Cancer Res Date: 2020-08-14 Impact factor: 12.531
Authors: Rebekka Götzl; Sebastian Sterzinger; Sabine Semrau; Nikolaos Vassos; Werner Hohenberger; Robert Grützmann; Abbas Agaimy; Andreas Arkudas; Raymund E Horch; Justus P Beier Journal: Health Qual Life Outcomes Date: 2019-11-08 Impact factor: 3.186
Authors: Richard F Riedel; Robin L Jones; Antoine Italiano; Chet Bohac; Juliette C Thompson; Kerstin Mueller; Zaeem Khan; Seth M Pollack; Brian A Van Tine Journal: Cancers (Basel) Date: 2018-11-01 Impact factor: 6.639
Authors: François Crettenand; David Martin; Stéphane Cherix; Nicolas Demartines; Maurice Matter Journal: J Cancer Date: 2018-09-07 Impact factor: 4.207